Berenberg Lifts BioNTech Target to $140 as Gotistobart Data Sharpens the Oncology Bet

Berenberg lifted its BioNTech target to $140 while BMO cut to $105, as Phase 3 lung cancer data showed 18.5-month median survival.

BioNTech's push to reinvent itself as an oncology player is drawing sharply divergent verdicts from the analyst community, even as fresh clinical data gives the bulls something concrete to work with.

Berenberg raised its price target on the Mainz-based biotech group from $132 to $140 on September 16, reiterating its buy rating. The private bank pointed to recent momentum in the company's clinical pipeline as a key pillar underpinning future valuation. The move places Berenberg firmly on the optimistic side of a debate that has been simmering for months.

Just over a week earlier, on September 8, BMO Capital Markets had moved in the opposite direction, downgrading the stock from "Outperform" to "Market Perform" and cutting its target from $128 to $105. The split verdicts underscore how unsettled investors remain about the pace of BioNTech's transformation away from its pandemic-era identity.

Oncology Readouts Anchor the Bull Case

The strongest operational argument for the optimists comes from lung cancer. Roughly a week ago, BioNTech and partner OncoC4 released updated results from the Phase 3 PRESERVE-003 trial in previously treated squamous lung cancer.

Their shared antibody candidate Gotistobart delivered a median overall survival of 18.5 months, against 10.0 months for patients on the chemotherapy Docetaxel — a near doubling of median survival. According to Reuters, the data, presented in Seoul, demonstrate a clinically meaningful advantage over the standard of care.

Proving therapeutic efficacy in late-stage trials carries outsized weight for BioNTech right now. With special revenue from COVID-19 vaccines fading, attention has shifted squarely to novel cancer therapies. Success in clinical testing is seen as the prerequisite for eventually returning to earlier earnings dimensions.

A Broader Pipeline, Not a Single Bet

BioNTech is not staking its future on one asset. At the International Association for the Study of Lung Cancer (IASLC) conference, the company also presented first data for a combination of Pumitamig and Elfetabart Drozuntecan in advanced and metastatic small cell lung cancer.

That expansion across different forms of lung cancer points to a methodical approach — testing combination therapies in segments with high unmet medical need rather than chasing speculative early-stage concepts. For market confidence, a steady flow of clinical readouts matters as much as any single result.

Insider Sales Follow a Pre-Set Plan

The clinical news has been accompanied by management transactions. BioNTech CEO Ugur Sahin sold 64,000 ordinary shares roughly a week ago, executed under a Rule 10b5-1 trading plan established on June 3, 2026, which fixes such transactions in advance. Sahin retains the bulk of his stake: through Medine GmbH, more than 39 million shares remain indirectly within his sphere of influence.

Where the Stock Stands

The equity has steadied after the recent catalysts. Shares are trading at EUR 85.65, about 1.2% above their 50-day moving average, and have gained 2.3% since the Phase 3 results were published roughly a week ago. The company carries a market capitalization of EUR 21.30 billion.

Weighing the current valuation, the opportunities appear to outweigh the risks. Setbacks in late-stage oncology trials can never be ruled out entirely, and the path to potential market approvals remains demanding. Still, the Gotistobart data and the advancing work on combination therapies show that the scientific foundation holds — and the pivot is taking tangible shape.